Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E. Dreyling M, et al. Among authors: hanel m. Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2. Lancet. 2024. PMID: 38705160 Free article. Clinical Trial.
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.
Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L. Korfel A, et al. Among authors: hanel m. Haematologica. 2013 Mar;98(3):364-70. doi: 10.3324/haematol.2012.077917. Epub 2012 Dec 14. Haematologica. 2013. PMID: 23242601 Free PMC article. Clinical Trial.
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, Hünerlitürkoglu AN, Schmitz N, Pöschel V, Rixecker T, Berdel C, Rübe C, Held G, Zwick C. Pfreundschuh M, et al. Among authors: hanel m. Br J Haematol. 2017 Nov;179(3):410-420. doi: 10.1111/bjh.14860. Epub 2017 Oct 8. Br J Haematol. 2017. PMID: 28990173 Free article. Clinical Trial.
Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hänel M, Bodenstein H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U. Kröger N, et al. Among authors: hanel m. J Clin Oncol. 2006 Aug 20;24(24):3919-26. doi: 10.1200/JCO.2005.04.0352. J Clin Oncol. 2006. PMID: 16921043 Clinical Trial.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Fenaux P, et al. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. Lancet Oncol. 2009. PMID: 19230772 Free PMC article. Clinical Trial.
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Lo-Coco F, et al. Among authors: hanel m. N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874. N Engl J Med. 2013. PMID: 23841729 Free article. Clinical Trial.
Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial.
Röllig C, Schäfer-Eckardt K, Hänel M, Kramer M, Schaich M, Thiede C, Oelschlägel U, Mohr B, Wagner T, Einsele H, Krause SW, Bodenstein H, Martin S, Stuhlmann R, Ho AD, Bornhäuser M, Ehninger G, Schuler U, Platzbecker U. Röllig C, et al. Among authors: hanel m. Ann Hematol. 2015 Apr;94(4):557-63. doi: 10.1007/s00277-014-2242-6. Epub 2014 Nov 5. Ann Hematol. 2015. PMID: 25366167 Clinical Trial.
Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization.
Heesch S, Neumann M, Schwartz S, Bartram I, Schlee C, Burmeister T, Hänel M, Ganser A, Heuser M, Wendtner CM, Berdel WE, Gökbuget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD. Heesch S, et al. Among authors: hanel m. Ann Hematol. 2013 Jun;92(6):747-58. doi: 10.1007/s00277-013-1694-4. Epub 2013 Feb 15. Ann Hematol. 2013. PMID: 23412561
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B. Shumilov E, et al. Among authors: hanel m. Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Online ahead of print. Blood Adv. 2024. PMID: 39661985
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7. Mai EK, et al. Among authors: hanel m. J Clin Oncol. 2024 Dec 9:JCO2402266. doi: 10.1200/JCO-24-02266. Online ahead of print. J Clin Oncol. 2024. PMID: 39652594
201 results